75 patents currently held
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
6
Ending by 2030
Oct 2027
Next term end
49
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2027 · High confidence
Also notable
Ends Feb 2035 · High confidence
Also notable
Ends Aug 2032 · High confidence
Also notable
Ends Oct 2030 · High confidence
Also notable
Ends Apr 2036 · High confidence
Also notable
Ends Oct 2037 · High confidence
Also notable
Ends Aug 2038 · High confidence
Also notable
Ends Aug 2036 · High confidence
Method for Determining Percent Platelet Aggregation
US 7,595,169
Cited by 57 later US patents, top 25% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Whole Blood Hemolysis Sensor
US 9,658,181
The largest patent family in this portfolio, 14 related applications, renewed at every maintenance window due so far. Protection runs to 2035.
System and Method of Increasing Sample Throughput
US 9,113,833
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2032.
Telescoping closed-tube sampling assembly
US 8,758,702
The most cited patent in this portfolio, cited by 79 later US patents, top 10% of utility patents granted in 2014 in our data. Protection runs to 2030.
Optical Flow Cell Apparatus and Method for Reducing Deflection of Sample Chamber
US 10,564,095
Granted 2020. Computed term ends 2036. A terminal disclaimer caps this term to an earlier patent's.
Total Protein Measurement Using Whole Blood Refractometry
US 10,168,278
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2037.
Dual Chamber Reagent Mixing Container
US 10,585,021
Granted 2020. Computed term ends 2038.
Reagent Component Dispensing Caps for Reagent Containers Used in Automated Clinical Analyzers
US 10,456,787
Granted 2019. Computed term ends 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Total Protein Measurement Using Whole Blood Refractometry (US 10,302,559) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 18, 2026The maintenance fee for Optical Flow Cell and Test Head Apparatus (US 10,324,025) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 2 fees due Feb 25, 2027
- 2 fees due Mar 5 to 19, 2027 · next Mar 5
- 1 fee due Apr 29, 2027The maintenance fee for Reagent Component Dispensing Caps for Reagent Containers Used in Automated Clinical Analyzers (US 10,456,787) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Optical Flow Cell Apparatus and Method for Reducing Deflection of Sample Chamber (US 10,564,095) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 3 fees due Sep 3 to 26, 2027 · next Sep 3
- 2 fees due Oct 16, 2027
- 1 fee due Nov 12, 2027The maintenance fee for Total Protein Measurement Using Whole Blood Refractometry (US 10,648,907) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 23, 2026
What they patent
The largest of its 49 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,595,169 | Method for Determining Percent Platelet Aggregation In force · High confidence | In force | High confidence | |
| US 9,817,010 | Telescoping closed-tube sampling assembly In force · Medium confidence | In force | Medium confidence | |
| US 7,858,037 | Adaptor for Sample Vial In force · High confidence | In force | High confidence | |
| US 10,578,605 | Cuvette-Based Apparatus for Blood Coagulation Measurement and Testing In force · Medium confidence | In force | Medium confidence | |
| US 11,402,369 | Cuvette-Based Apparatus for Blood Coagulation Measurement and Testing In force · Medium confidence | In force | Medium confidence | |
| US 8,758,702 | Telescoping closed-tube sampling assembly In force · High confidence | In force | High confidence | |
| US 10,180,419 | Cuvette-Based Apparatus for Blood Coagulation Measurement and Testing In force · Medium confidence | In force | Medium confidence | |
| US 9,113,834 | System and Method of Increasing Sample Throughput by Estimation of a Sensor Endpoint In force · Medium confidence | In force | Medium confidence | |
| US 8,560,251 | System and Method of Increasing Sample Throughput by Estimation of a Sensor Endpoint In force · High confidence | In force | High confidence | |
| US 9,113,833 | System and Method of Increasing Sample Throughput In force · High confidence | In force | High confidence |
Also on record, not counted in the 75: 5 patents in force now held by others · 41 patents ended · 24 applications pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.